8月31日,港交所又迎来一家递表的中国生物医药企业:甫康生物。这是一家主要从事肿瘤药物开发的药企,首款商业化产品是一款仿制药:马来酸奈拉替尼“汉奈佳”,2024年6月获批上市,用于HER2阳性乳腺癌的一线强化辅助治疗。目前,汉奈佳在国内的商业化权益已经被复宏汉霖收入囊中,与曲妥珠单抗类似药汉曲优形成“优佳组合“。上市一年时间里,汉奈佳为甫康生物贡献了5250万元收入,全部来自复宏汉霖的销售分成。...
Source Link8月31日,港交所又迎来一家递表的中国生物医药企业:甫康生物。这是一家主要从事肿瘤药物开发的药企,首款商业化产品是一款仿制药:马来酸奈拉替尼“汉奈佳”,2024年6月获批上市,用于HER2阳性乳腺癌的一线强化辅助治疗。目前,汉奈佳在国内的商业化权益已经被复宏汉霖收入囊中,与曲妥珠单抗类似药汉曲优形成“优佳组合“。上市一年时间里,汉奈佳为甫康生物贡献了5250万元收入,全部来自复宏汉霖的销售分成。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.